| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 35.25 | -0.46 (-1.29%) | 18.52 - 42.41 | 514.2 thousand (Below Avg) |
Market data as of 4:00PM 06/19/13. Quotes are delayed by at least 15 min.
| Open | 35.78 |
|---|---|
| Previous Close | 35.71 |
| Day's Range | 35.10 - 35.96 |
| Market Cap | 3.5B |
| Avg Volume (10 Day) | 1.1M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.52 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
No news headlines available for THRX
| THRX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -93.12% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 5.03 | |
| LT Debt/Equity | 5.03 | |
| Earnings Yield | -- | |
| Price/Sales | 355.08 |
| Company | Last | Change |
|---|---|---|
| Medivation Inc | 46.58 | -4.45% |
| ARIAD Pharmaceuticals Inc | 17.22 | -3.18% |
| Seattle Genetics Inc | 31.49 | -2.20% |
| Jazz Pharmaceuticals PLC | 68.28 | -1.98% |
| Incyte Corp | 20.36 | -4.90% |
Data is delayed by at least 15 min.